دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
President's Message: Amplifying SCAI's DEI Efforts
Cindy L. Grines MD, MSCAI,
doi : 10.1002/ccd.29787
Volume 98, Issue 3 p. 413-413
SCAI COVID 19 Updated Consumer Survey Shows Continued Concern of Patients, Especially among Underserved Populations
Cindy L. Grines MD, MSCAI
doi : 10.1002/ccd.29788
Volume 98, Issue 3 p. 414-415
Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF
David E. Kandzari MD,Raymond R. Townsend MD,George Bakris MD,Jan Basile MD,Michael J. Bloch MD,Debbie L. Cohen MD,Cara East MD,Keith C. Ferdinand MD,Naomi Fisher MD,Ajay Kirtane MD,David P. Lee MD,Gary Puckrein PhD,Florian Rader MD, MSc,Joseph A. Vassalotti MD,Michael A. Weber MD,Kerry Willis MD,Eric Secemsky MD,
doi : 10.1002/ccd.29884
Volume 98, Issue 3 p. 416-426
Long-term follow-up of percutaneous coronary intervention versus coronary artery bypass grafting in left main coronary artery disease: A systematic review and meta-analysis
Aakash Garg MD,Amit Rout MD,Hitesh Raheja MD,Hisham Hakeem MD,Samin Sharma MD,
doi : 10.1002/ccd.29338
Volume 98, Issue 3 p. 427-433
We conducted a systematic review and meta-analysis to evaluate the long-term outcomes of PCI compared to CABG in patients with LMCAD.
Percutaneous coronary intervention versus coronary artery bypass graft surgery: The battle rages on
Giuseppe Tarantini MD, PhD,Vittorio Zuccarelli MD,
doi : 10.1002/ccd.29883
Volume 98, Issue 3 p. 434-435
Coronary anatomy and comorbidities impact on elective PCI outcomes in left main and multivessel coronary artery disease
Neil Yager DO,Joshua Schulman-Marcus MD,Mikhail Torosoff MD, PhD,
doi : 10.1002/ccd.29368
Volume 98, Issue 3 p. 436-444
The effects of coronary anatomy, lesion complexity, and comorbidities on outcomes of elective percutaneous coronary intervention (PCI) in high-risk patients with left main (LM) and/or multivessel coronary artery disease (CAD) are not well studied, as these patients are typically underrepresented in the clinical trials.
Percutaneous coronary intervention outcomes in left main and multivessel disease: Navigating the patent minefield
Giuseppe Musumeci MD,Marzia Colopi MD,
doi : 10.1002/ccd.29881
Volume 98, Issue 3 p. 445-446
Long-term clinical outcomes of coronary artery bypass graft surgery compared to those of percutaneous coronary intervention with second generation drug eluting stents in patients with stable angina and an isolated lesion in the proximal left anterior descending artery
Ioannis L. Matsoukis MD,Antonios Karanasos MD,Chrysoula Patsa MD,Nikolaos Anousakis-Vlachochristou MD,Konstantinos Triantafyllou MD,Maria Kantzanou MD,Maria Drakopoulou MD,Eleftherios Tsiamis MD,George Latsios MD,Andreas Synetos MD,Eleni Th Petridou MD,Dimitris Tousoulis MD,Konstantinos Toutouzas MD,
doi : 10.1002/ccd.29247
Volume 98, Issue 3 p. 447-457
We compared the long-term outcomes of percutaneous coronary intervention with second-generation drug-eluting stents (PCI-DES) and coronary artery bypass graft surgery (CABG) with the left internal mammary artery in stable angina patients with isolated single-vessel proximal left anterior descending artery (pLAD) disease.
Impact of stent designs of second-generation drug-eluting stents on long-term outcomes in coronary bifurcation lesions
Woo Jin Jang MD,Woo Jung Chun MD,Ik Hyun Park MD,Ki Hong Choi MD,Young Bin Song MD,Bon-Kwon Koo MD,Joon-Hyung Doh MD,Soon-Jun Hong MD,Chang-Wook Nam MD,Hyeon-Cheol Gwon MD,
doi : 10.1002/ccd.29137
Volume 98, Issue 3 p. 458-467
We compared the long-term clinical outcomes of four different types of second-generation drug-eluting stents (DESs) in coronary bifurcation lesions.
This is the best generation, for now
Samuel M. Butman MD, FSCAI
doi : 10.1002/ccd.29882
Volume 98, Issue 3 p. 468-469
Trends of repeat revascularization choice in patients with prior coronary artery bypass surgery
Mohamed O. Mohamed MRCP,Ahmad Shoaib MD,Bill Gogas MD,Tejas Patel MD,M Chadi Alraies MD,Poonam Velagapudi MD,Sanjay Chugh MD,Kamal Sharma MD, DM,Walid Mohamed MRCS,Gavin J. Murphy MD,Chun Shing Kwok MRCP,Muhammad Rashid PhD,Rodrigo Bagur MD, PhD,Mamas A. Mamas DPhil,
doi : 10.1002/ccd.29234
Volume 98, Issue 3 p. 470-480
To examine rates and predictors repeat revascularization strategies (percutaneous coronary intervention [PCI] and coronary artery bypass grafting [CABG]) in patients with prior CABG.
The first cut is the deepest (and perhaps the most opportune)!
Robert F. Riley MD, MS,Timothy D. Henry MD,
doi : 10.1002/ccd.29880
Volume 98, Issue 3 p. 481-482
Left coronary artery calcification patterns after coronary bypass graft surgery: An in-vivo optical coherence tomography study
Rafal Wolny MD, PhD,Gary S. Mintz MD,Mitsuaki Matsumura BS,Song-Yi Kim MD,Masaru Ishida MD,Akiko Fujino MD,Tetsumin Lee MD,Evan Shlofmitz DO,Alec Goldberg BS,Yangbo Liu MS,Zixuan Zhang MS,Mingyou Zhang MD,Xun Hu MD,Allen Jeremias MD, MSc,George Petrossian MD,Richard A. Shlofmitz MD,Akiko Maehara MD,
doi : 10.1002/ccd.29220
Volume 98, Issue 3 p. 483-491
We sought to evaluate the severity and patterns of calcifications in the left main coronary artery (LMCA) and proximal segments of left anterior descending coronary artery (LAD) and left circumflex artery (LCX) using optical coherence tomography (OCT) in patients with and without prior coronary artery bypass grafting (CABG).
Coronary bypass graft surgery accentuates proximal coronary disease progression!
Yoshiyuki Okuya MD,Issam D. Moussa MD,
doi : 10.1002/ccd.29875
Volume 98, Issue 3 p. 492-492
Clinical implication of neointimal burden in in-stent restenosis treated with drug-coated balloon
Jung-Hee Lee MD, PhD,Ung Kim MD, PhD,Jung-Sun Kim MD, PhD,Sung-Jin Hong MD, PhD,Chul-Min Ahn MD, PhD,Byeong-Keuk Kim MD, PhD,Young-Guk Ko MD, PhD,Donghoon Choi MD, PhD,Myeong-Ki Hong MD, PhD,Yangsoo Jang MD, PhD
doi : 10.1002/ccd.29211
Volume 98, Issue 3 p. 493-502
Although drug-coated balloon (DCB) angioplasty is a well-established drug-eluting stent (DES) in-stent restenosis (ISR) strategy, there are minimal data regarding the association of neointimal burden on optical coherence tomography (OCT) before and after DCB and adverse clinical events. This study aimed to investigate the clinical impact of neointimal burden measured with OCT in patients with DES ISR after DCB angioplasty.
Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent
Laura S.M. Kerkmeijer MD,Jaya Chandrasekhar MBBS, MS,Deborah N. Kalkman MD, PhD,Pier Woudstra MD, PhD,Ian B.A. Menown MD,Harry Suryapranata MD, PhD,Peter den Heijer MD, PhD,Andrés I?iguez MD, PhD,Arnoud W.J. van 't Hof MD, PhD,Andrejs Erglis MD,Karin E. Arkenbout MD, PhD,Philippe Muller MD,Karel T. Koch MD, PhD,Jan G. Tijssen PhD,Marcel A.M. Beijk MD, PhD,Robbert J. de Winter MD, PhD
doi : 10.1002/ccd.29305
Volume 98, Issue 3 p. 503-510
This final report from the REMEDEE Registry assessed the long-term safety and efficacy of the dual-therapy COMBO stent in a large unselected patient population.
Three-year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry
Thibault Lhermusier MD, PhD,Didier Carrie MD, PhD,Guillaume Cayla MD, PhD,Jean Fajadet MD,Joel Sainsous MD,Simon Elhadad MD,Francois Tarragano MD,Bernard Chevalier MD,Sylvain Ranc MD,Corentin Curinier MD,Herve Le Breton MD, PhD,Rene Koning MD,The FRANCE ABSORB Investigators, … See fewer authors
doi : 10.1002/ccd.29369
Volume 98, Issue 3 p. 511-519
The aim of this study was to determine the 3-year outcomes of patients treated with Absorb bioresorbable vascular scaffold (BVS) implantation.
The case for a qualitative lesion assessment system for coronary angiography
Tara L. Jones MD, PharmD,Mordechai Golomb MD,Elizabeth Dranow PhD,Frederick G.P. Welt MD,Pinak B. Shah MD,
doi : 10.1002/ccd.29334
Volume 98, Issue 3 p. 520-525
Since the advent of coronary angiography, the standard for reporting of coronary lesion severity has been to utilize percent diameter stenosis (%DS). Given the imperfections of %DS as well as the widespread availability of intraprocedural intracoronary imaging and physiology assessment, it is time to consider a simpler yet more clinically relevant lesion assessment system. We compiled ten actual cases and presented these cases to 10 operators, providing 100 independent lesion assessments. For each case, operators were asked to describe lesions using %DS and a simplified lesion assessment system. We assessed the relationship between %DS and qualitative lesion assessment as well as the relationship of both measurements to the chosen plan. Greater variability exists with %DS than with qualitative lesion assessment. Despite this, there is good correlation between %DS and the qualitative lesion assessment (? = 0.8221). There remains overlap of lesion assessment using the qualitative lesion assessment tool suggesting that even with this simpler tool, there remains interobserver variability (ICC = 0.5164, 95% confidence interval [CI] 0.2924-0.7955). When assessing how both lesion assessment, there appears to be a stronger correlation between the qualitative lesion assessment and the chosen plan versus the %DS and the chosen plan (? = 0.9069 vs ? = 0.8001, P?<?.01). Given the superior performance of the proposed qualitative system and the ability to estimate lesion severity using both anatomic and clinical factors, we feel that professional societies and clinicians should begin to embrace this simplified means of lesion assessment.
Cutting balloon angioplasty on branch pulmonary artery stenosis in pediatric patients
Harrison Cobb MD,Beverly Spray PhD,Joshua Daily MD,Amy Dossey MD,Michael J. Angtuaco MD,
doi : 10.1002/ccd.29803
Volume 98, Issue 3 p. 526-532
To identify medium-term results following cutting balloon angioplasty (CBA) for branch pulmonary artery stenosis (PAS) and predictors of successful intervention.
Deformation and stenosis of the sinus-SuperFlex-DS stent after ductal stenting for the hybrid stage 1 procedure
Ines Hribernik MD,John Thomson MD,James Bentham MD, PhD,
doi : 10.1002/ccd.29806
Volume 98, Issue 3 p. 533-539
We present five cases of sinus-SuperFlex-DS stent stenosis during early follow up that resulted in inadequate ductal patency and required urgent re-stenting with a balloon-expandable stent. This causes concern that these stents lack sufficient radial force against ductal constriction and if used need to be kept under close scrutiny.
Trends and causes of readmission following peripheral vascular intervention in patients with peripheral vascular disease
Homam Moussa Pacha MD,Tanveer Mir MD,Yasser Al-khadra MD,Yasar Sattar MD,Waqas Ullah MD,Nathan Zaher MD,Bachar Ahmad BS,Abdul-Rahman M. Suleiman BS,Fahed Darmoch MD,Mohamad Soud MD,Haroon Faraz MD,Zaher Hakim MD,M. Chadi Alraies MD,
doi : 10.1002/ccd.29698
Volume 98, Issue 3 p. 540-548
To study the risk factors associated with 30-readmission postperipheral vascular intervention (PVI) in peripheral artery disease (PAD).
Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study
Krishna J. Rocha-Singh MD,Ravish Sachar MD,Brian G. DeRubertis MD,Claus C. A. Nolte-Ernsting MD,John G. Winscott MD,Prakash Krishnan MD,Eric C. Scott MD,Lawrence A. Garcia MD,Jean-Luc Baeriswyl MSc,Gary Ansel MD,Kenneth Rosenfield MD,Thomas Zeller MD,The REALITY Investigators
doi : 10.1002/ccd.29777
Volume 98, Issue 3 p. 549-558
Drug coated balloon (DCB) angioplasty significantly reduces reintervention rates in patients with symptomatic femoropopliteal peripheral artery disease (PAD). However, stand-alone DCB use in long, severely calcified lesions is frequently associated with vessel recoil and/or high-grade dissections necessitating provisional stent implantation.
Anterior, posterior, or all-vessel infrapopliteal revascularization in patients with moderate-severe claudication: Insights from the LIBERTY 360 study
Taufiq Salahuddin MD,Stefanos Giannopoulos MD,George Adams MD, MHS,Ehrin J. Armstrong MD, MSc,
doi : 10.1002/ccd.29780
Volume 98, Issue 3 p. 559-569
Little data guides revascularization of infrapopliteal peripheral arterial disease (PAD) in patients with claudication. We assessed outcomes after infrapopliteal-only intervention for claudication in the LIBERTY 360 observational study.
Below the knee percutaneous transluminal angioplasty for claudicants: One vessel is enough to relieve symptoms
Eugenio Stabile MD, PhD,Giovanni Esposito MD, PhD,
doi : 10.1002/ccd.29876
Volume 98, Issue 3 p. 570-571
Real-world experience of suture-based closure devices: Insights from the FDA Manufacturer and User Facility Device Experience
Brian C. Case MD,Sant Kumar BA,Charan Yerasi MD,Brian J. Forrestal MBBS,Anees Musallam MD,Chava Chezar-Azerrad MD,Nauman Khalid MD,Evan Shlofmitz DO,Yuefeng Chen MD, PhD,Jaffar M. Khan BM BCh, PhD,Lowell F. Satler MD,Itsik Ben-Dor MD,Hayder Hashim MD,Nelson L. Bernardo MD,Toby Rogers MD, PhD,Ron Waksman MD
doi : 10.1002/ccd.29501
Volume 98, Issue 3 p. 572-577
We analyzed post-marketing surveillance data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database for suture-based vascular closure devices (VCDs) – Perclose ProGlide (Abbott, Chicago, Illinois) and Prostar XL (Abbott).
A stitch in time saves… uncontrollable blood loss
Arnold H. Seto MD, MPA, FSCAI, FACC,David M. Tehrani MD, MS,
doi : 10.1002/ccd.29871
Volume 98, Issue 3 p. 578-579
Propensity-matched comparison of large-bore access closure in transcatheter aortic valve replacement using MANTA versus Perclose: A real-world experience
Giorgio A. Medranda MD,Brian C. Case MD,Cheng Zhang PhD,Hank Rappaport MD, MS,Gaby Weissman MD,Nelson L. Bernardo MD,Lowell F. Satler MD,Itsik Ben-Dor MD,Toby Rogers MD, PhD,Ron Waksman MD,
doi : 10.1002/ccd.29786
Volume 98, Issue 3 p. 580-585
Compare two large-bore vascular closure devices (VCDs), collagen-plug-based MANTA and suture-based dual Perclose ProGlide (PP), in patients undergoing contemporary transfemoral transcatheter aortic valve replacement (TAVR).
MANTA versus Perclose for large-bore vessel closure: The evidence continues to grow
Alexander Postalian MD,Zvonimir Krajcer MD,
doi : 10.1002/ccd.29877
Volume 98, Issue 3 p. 586-587
Transcatheter pulmonary denervation in patients with left heart failure with reduced ejection fraction and combined precapillary and postcapillary pulmonary hypertension: A prospective single center experience
Adam Witkowski MD, PhD, FESC,?ukasz Szumowski MD, PhD,Piotr Urbanek MD, PhD,Jan Jastrz?bski MD,Jaros?aw Skowro?ski MD,Ma?gorzata Sobieszcza?ska-Ma?ek MD, PhD,Piotr Hoffman MD, PhD, FESC,Ewa Kowalik MD, PhD,Joanna Wi?niewska MD, PhD,Adam Banasiak MD,Adam Parulski MD,Tomasz Zieli?ski MD, PhD
doi : 10.1002/ccd.29526
Volume 98, Issue 3 p. 588-594
The present study was a prospective, single-center, single-arm study to investigate the efficacy of transcatheter pulmonary artery denervation (TPADN) in patients with combined postcapillary and precapillary PH (Cpc-PH) associated with left heart failure with reduced ejection fraction (HF-rEF).
Computed tomography analysis of coronary ostia location following valve-in-valve transcatheter aortic valve replacement with the ACURATE neo valve: Implications for coronary access
Arif A. Khokhar BMBCh,Alessandra Laricchia MD,Francesco Ponticelli MD,Won-Keun Kim MD,Francesco Gallo,Damiano Regazzoli MD,Marco Toselli MD,Alessandro Sticchi MD,Rossella Ruggiero MD,Alberto Cereda MD,Adriana Zlahoda-Huzior MD,Andrea Fisicaro MD,Ilja Gardi MD,Antonio Mangieri MD,Bernhard Reimers MD,Dariusz Dudek MD,Antonio Colombo MD,Francesco Giannini MD
doi : 10.1002/ccd.29503
Volume 98, Issue 3 p. 595-604
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is an emerging alternative to re-do surgery. However, the challenge of coronary access (CA) following ViV-TAVR is a potential limitation as TAVR expands to younger lower-risk populations.
Coronary access after valve-in-valve transcatheter aortic valve replacement: Time for a prospective study?
Gilbert H. L. Tang MD, MSc, MBA, FSCAI,George D. Dangas MD, PhD, MSCAI,
doi : 10.1002/ccd.29879
Volume 98, Issue 3 p. 605-606
Readmission following urgent transcatheter aortic valve implantation versus urgent balloon aortic valvuloplasty in patients with decompensated heart failure or cardiogenic shock
Sandipan Chakraborty MBBS, MD,Neelkumar Patel MD,Dhrubajyoti Bandyopadhyay MBBS, MD,Adrija Hajra MBBS, MD, MRCP (UK),Birendra Amgai MD,Syed Zaid MBBS,Parija Sharedalal MD,Hasan Ahmad MD,Martin B. Cohen MD,J. Dawn Abbott MD,Srihari S. Naidu MD
doi : 10.1002/ccd.29690
Volume 98, Issue 3 p. 607-612
Urgent transcatheter aortic valve implantation (TAVI) is a feasible option for aortic stenosis (AS) patients with decompensated heart failure (HF) and cardiogenic shock (CS) as compared to the more traditional urgent balloon aortic valvuloplasty (BAV).
Optimal management of acute decompensated aortic stenosis
Mohamad Alkhouli MD,Hani Jneid MD,
doi : 10.1002/ccd.29878
Volume 98, Issue 3 p. 613-614
Misconception in CrossBoss/stingray catheter use-clarification from the hybrid group
Ashish Pershad MD, MS,James A. Grantham MD, FACC,Craig A. Thompson MD, MS,William L. Lombardi MD, FACC,
doi : 10.1002/ccd.29560
Volume 98, Issue 3 p. 615-615
Rebuttal: Misconceptions in crossboss/stingray catheter use—Clarification from the hybrid group
Eugene B. Wu MD
doi : 10.1002/ccd.29562
Volume 98, Issue 3 p. 616-616
The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents
Minkwan Kim MD, PhD,Kyung Woo Park MD, PhD,Hak Seung Lee MD,You-Jeong Ki MD,Jeehoon Kang MD, PhD,Chee-Hoon Kim MD,Jung-Kyu Han MD, PhD,Han-Mo Yang MD, PhD,Hyun-Jae Kang MD, PhD,Bon-Kwon Koo MD, PhD,Hyo-Soo Kim MD, PhD
doi : 10.1002/ccd.29682
Volume 98, Issue 3 p. E332-E341
We investigated whether the dual antiplatelet therapy (DAPT) score (DS) predicts clinical outcome in an East-Asian population that received exclusively second generation drug-eluting stent (DES).
Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score
Alberto Cordero MD, PhD, FESC,Belén Cid-Alvarez MD, PhD,Eduardo Alegr?a MD, PhD,Agust?n Fern?ndez-Cisnal MD,David Escribano MD,Jenniffer Bautista MD,Maria Juskova MD,Ramiro Trillo MD, PhD, FESC,Vicente Bertomeu-Gonzalez MD, PhD, FESC,José Luis Ferreiro MD, PhD, FESC
doi : 10.1002/ccd.29689
Volume 98, Issue 3 p. E342-E350
Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT.
Changes in surgical revascularization strategy after fractional flow reserve
Stephane Fournier MD,Gabor G Toth MD/PhD,Bernard De Bruyne MD/PhD,Petr Kala MD,Flavio L Ribichini MD,Filip Casselman MD,Ruben Ramos MD,Zsolt Piroth MD,Anna Piccoli MD,Martin Penicka MD/PhD,Martin Mates MD,Petr Nemec MD,Frank Van Praet MD,Bernard Stockman MD,Ivan Degriek MD,Mariano Pellicano MD/PhD,Emanuele Barbato MD/PhD
doi : 10.1002/ccd.29694
Volume 98, Issue 3 p. E351-E355
In the randomized GRAFFITI trial, surgeons drew their strategy based on coronary angiography. When patients were randomized to fractional flow reserve (FFR)-guidance, surgeons were informed of the FFR values and asked to redraw their strategy. The aim of this study was to investigate the changes induced by FFR knowledge.
In-hospital outcomes and usage of embolic protection devices in percutaneous coronary intervention for coronary artery bypass grafts: Insights from a Japanese nationwide registry
Yusuke Oba MD, PhD,Taku Inohara MD, PhD,Masao Takahashi MD, PhD,Motoki Fukutomi MD, PhD,Hiroshi Funayama MD, PhD,Hirohiko Ando MD, PhD,Shun Kohsaka MD, PhD,Tetsuya Amano MD, PhD,Yuji Ikari MD, PhD,Kazuomi Kario MD, PhD
doi : 10.1002/ccd.29695
Volume 98, Issue 3 p. E356-E364
We evaluated the in-hospital outcomes of percutaneous coronary intervention (PCI) for bypass graft vessels (GV-PCI) compared with those of PCI for native vessels (NV-PCI) using data from the Japanese nationwide coronary intervention registry.
Coronary sinus size and ischemia improvement after reducer implantation; “one size to fit them all?”
Georgios Tzanis MD,Arif A Khokhar BM, BCh,Francesco Ponticelli MD,Guglielmo Gallone MD,Anna Palmisano MD,Antonio Esposito MD,Alessandro Beneduce MD,Stefano Guarracini MD,Antonio Colombo MD,Francesco Giannini MD
doi : 10.1002/ccd.29699
Volume 98, Issue 3 p. E365-E369
Coronary sinus (CS) reducer implantation is associated with symptomatic relief of patients with refractory angina. However, 15% to 30% of the patients do not respond to this treatment. Aim if this study was to evaluate the effect of CS size in the effectiveness of the device.
Patients with COVID-19 who experience a myocardial infarction have complex coronary morphology and high in-hospital mortality: Primary results of a nationwide angiographic study
Alexandre Abizaid MD, PhD,Carlos M. Campos MD, PhD,Patr?cia O. Guimar?es MD, PhD,José de Ribamar Costa Jr. PhD, MD,Breno A. A. Falc?o MD, PhD,Fernanda Mangione MD,Adriano Caixeta MD, PhD,Pedro A. Lemos MD, PhD,Fabio S. de Brito Jr. MD, PhD,Ricardo Cavalcante MD,Cristiano Guedes Bezerra MD, PhD,Leandro Cortes MD,Henrique B. Ribeiro MD, PhD,Francis R. de Souza PhD,Natassja Huemer BS,Renata M. do Val BS,Bruno Caramelli MD, PhD,Daniela Calderaro MD, PhD,Felipe G. Lima MD,Ludhmila A. Hajjar MD, PhD,Roxana Mehran MD,Roberto Kalil Filho MD, PhD,the COVID MI investigators,
doi : 10.1002/ccd.29709
Volume 98, Issue 3 p. E370-E378
We aimed to explore angiographic patterns and in-hospital outcomes of patients with concomitant coronavirus disease-19 (COVID-19) and myocardial infarction (MI).
Impact of stent length and diameter on 10-year mortality in the SYNTAXES trial
Hironori Hara MD,Masafumi Ono MD,Hideyuki Kawashima MD,Norihiro Kogame MD,Michael J. Mack MD,David R. Holmes MD,Marie-Claude Morice MD,Piroze M. Davierwala MD,Friedrich W. Mohr MD, PhD,Daniel J.F.M. Thuijs MD,Stuart J. Head MD, PhD,Arie Pieter Kappetein MD, PhD,Yoshinobu Onuma MD, PhD,Patrick W. Serruys MD, PhD,for the SYNTAX Extended Survival Investigators,
doi : 10.1002/ccd.29721
Volume 98, Issue 3 p. E379-E387
We investigated the impact of total stent length (TSL) and average nominal stent diameter (ASD) on 10-year mortality after percutaneous coronary intervention (PCI) in the SYNTAXES trial.
Future culprit detection based on angiography-derived FFR
Mattia Pagnoni MD,David Meier MD,Alessandro Candreva MD,Luc Maillard MD, PhD,Julien Adjedj MD, PhD,Carlos Collet MD, PhD,Thabo Mahendiran MD,Stephane Cook MD,Alma Mujcinovic BMed,Marion Dupré MD,Vladimir Rubimbura MD,Christan Roguelov MD,Eric Eeckhout MD, PhD,Bernard De Bruyne MD, PhD,Olivier Muller MD, PhD,Stephane Fournier MD,
doi : 10.1002/ccd.29736
Volume 98, Issue 3 p. E388-E394
We sought to characterize the hemodynamic impact of mild coronary artery disease (CAD) using quantitative flow ratio (QFR, an angiography-derived fractional flow reserve [FFR]) in a population of patients with only non-significant CAD at baseline that subsequently experienced a myocardial infarction (MI).
New lesion after endovascular therapy of femoropopliteal lesions for intermittent claudication
Tomonori Katsuki MD,Kyohei Yamaji MD, PhD,Yoshimitsu Soga MD, PhD,Osamu Iida MD,Masahiko Fujihara MD,Daizo Kawasaki MD, PhD,Kenji Ando MD,
doi : 10.1002/ccd.29765
Volume 98, Issue 3 p. E395-E402
Although the incidence of target lesion revascularization (TLR) was decreased in patients who underwent endovascular therapy (EVT) for femoropopliteal (FP) lesions, the clinical impact of newly developed lesions could not be disqualified in those patients.
One-year clinical and echocardiographic outcomes of direct implantation of a self-expanding valve
Georgios Benetos MD,Maria Karmpalioti MD,Maria Drakopoulou MD,Konstantinos Stathogiannis MD,Maria Xanthopoulou MD,George Latsios MD,Andreas Synetos MD,Evangelia Bei MD,Vassilis Voudris MD,Ioannis Iakovou MD,Georgios Katsimagklis MD,Sotiris Moraitis MD,Vicki Zeniou MD,Haim Danenberg MD,Panagiotis Halvatsiotis MD,Manolis Vavuranakis MD,Dimitris Tousoulis MD,Konstantinos Toutouzas MD,
doi : 10.1002/ccd.29389
Volume 98, Issue 3 p. E403-E411
To present 1?year clinical and echocardiographic outcomes of the randomized DIRECT (Pre-dilatation in Transcatheter Aortic Valve Implantation Trial) trial.
Association of heart failure duration with clinical outcomes after transcatheter mitral valve repair for functional mitral regurgitation
Atsushi Sugiura MD, PhD,Marcel Weber MD,Noriaki Tabata MD, PhD,Tadahiro Goto MD, MPH, PhD,Eberhard Grube MD,Hendrik Treede MD,Nikos Werner MD,Georg Nickenig MD,Jan-Malte Sinning MD,
doi : 10.1002/ccd.29390
Volume 98, Issue 3 p. E412-E419
Little is known about the association of heart failure (HF) chronicity with clinical outcomes after transcatheter mitral valve repair (TMVR) for functional mitral regurgitation (MR).
Imaging risk features for device related pulmonary artery injury after left atrial appendage closure with Amplatzer™ Amulet™ device
Rados?aw Praco? MD PhD,Ole De Backer MD PhD,Marek Konka MD PhD,Cezary K?pka MD PhD,Mariusz Kruk PhD,Piotr Trochimiuk MD,Mariusz D?bski MD PhD,Zofia Dzieli?ska MD PhD,Lars S?ndergaard MD PhD,Marcin Demkow MD PhD
doi : 10.1002/ccd.29393
Volume 98, Issue 3 p. E420-E426
This study aimed to find imaging risk features for device related-pulmonary artery (PA) injury (DR-PAI) in patients after left atrial appendage closure (LAAC).
Tricuspid regurgitation after transcatheter mitral valve repair: Clinical course and impact on outcome
Frank Meijerink MD,Karel T. Koch MD, PhD,Robbert J. de Winter MD, PhD,Daniëlle Robbers-Visser MD, PhD,S. Matthijs Boekholdt MD, PhD,Marja Holierook MSc,Jan Baan MD, PhD,Berto J. Bouma MD, PhD,
doi : 10.1002/ccd.29464
Volume 98, Issue 3 p. E427-E435
The aim of this study was to determine the course of tricuspid regurgitation (TR) after transcatheter mitral valve repair (TMVR), identify predictors for severe TR after TMVR and determine the association of severe TR after TMVR with outcome.
Comparing outcomes of general anesthesia and monitored anesthesia care during transcatheter aortic valve replacement: The Cleveland Clinic Foundation experience
Yasser Sammour MD,Jimmy Kerrigan MD,Kinjal Banerjee MD,Rama Dilip Gajulapalli MD,Hassan Lak MD,Sanchit Chawla MD,Krystof Andress MD,Neha Gupta MD,Shinya Unai MD,Lars G. Svensson MD,James Yun MD,Grant W Reed MD,Andrej Alfirevic MD,Shiva Sale MD,Anand Mehta MD,Amar Krishnaswamy MD,Nikolaos Skubas MD,Samir Kapadia MD,
doi : 10.1002/ccd.29496
Volume 98, Issue 3 p. E436-E443
Monitored anesthesia care (MAC) has become more widely used during transcatheter aortic valve replacement (TAVR) to avoid the complications of general anesthesia (GA).
Survival relative to pacemaker status after transcatheter aortic valve implantation
Aung Myat MD,Florence Mouy BMBS,Luke Buckner BMBS,James Cockburn MD,Andreas Baumbach MD,Philip MacCarthy PhD,Adrian P. Banning MD,Nick Curzen PhD,Roland Hilling-Smith MD,Daniel J. Blackman MD,Michael Mullen MD,Mark de Belder MD,Ian Cox MD,Jan Kovac MD,Ganesh Manoharan MD,Azfar Zaman MD,Douglas Muir MBChB,David Smith MD,Stephen Brecker MD,Mark Turner PhD,Saib Khogali MD,Iqbal S. Malik PhD,Osama Alsanjari MRCP,Francesca D'Auria PhD,Simon Redwood MD,Bernard Prendergast DM,Uday Trivedi MD,Derek Robinson DPhil,Peter Ludman MD,Adam de Belder MD,David Hildick-Smith MD
doi : 10.1002/ccd.29498
Volume 98, Issue 3 p. E444-E452
To determine whether a permanent pacemaker (PPM) in situ can enhance survival after transcatheter aortic valve implantation (TAVI), in a predominantly inoperable or high risk cohort.
Effect of institutional transcatheter aortic valve replacement volume on mortality: A systematic review and meta-analysis
Devika Kir MD,Kayle Shapero MD, PhD,Saurav Chatterjee MD,Alyssa Grimshaw MSLIS,August Oddleifson,Erica S. Spatz MD, MHS,Andrew M. Goldsweig MD,Nihar R. Desai MD, MPH
doi : 10.1002/ccd.29502
Volume 98, Issue 3 p. E453-E461
We sought to conduct a systematic review and network meta-analysis to examine the association between institutional transcatheter aortic valve replacement (TAVR) volume and all-cause mortality.
Reduction of MANTA-associated vascular complications after implementation of key insights on failure mechanisms
Federico Moccetti MD,Mathias Wolfrum MD,Matthias Bossard MD,Adrian Attinger-Toller MD,Benjamin Berte MD,Florim Cuculi MD,Richard Kobza MD,Stefan Toggweiler MD,
doi : 10.1002/ccd.29696
Volume 98, Issue 3 p. E462-E465
Report MANTA-associated vascular complications after implementation of key insights on failure mechanisms.
Hybrid treatment of aortic aneurism, type-A dissection, and aortic valve stenosis
Mattia Lunardi MD,Ilaria Franzese MD,Giuseppe Faggian MD,Flavio L. Ribichini MD,
doi : 10.1002/ccd.29303
Volume 98, Issue 3 p. E466-E470
Hybrid multidisciplinary interventions are attractive care options for heart valve and vascular diseases in high-risk patients. We describe the feasibility of staged hybrid aortic arch repair to treat a type Ia endoleak and transcatheter aortic valve replacement to treat an aortic valve stenosis, achieving an escape strategy to treat an unexpected type-A aortic dissection.
Plaster pipes and crystalized graphite: Open transventricular transcatheter aortic valve replacement for failed mechanical aortic valve prostheses in the porcelain aorta
Matthew S. Yong MBBS,Anthony C. Camuglia MBBS, MHA, FRACP, FCSANZ,Stephen V. Cox MBBS, FRACP, FCSANZ,Christopher M. Cole BA, MBBS, FRACS,
doi : 10.1002/ccd.29465
Volume 98, Issue 3 p. E471-E474
Patients with a true porcelain aorta and a failed mechanical aortic valve prosthesis have limited treatment options. Using a hybrid of an open trans-ventricular approach with peripheral cardiopulmonary bypass and integration of transcatheter techniques this challenge can be overcome. Trans-ventricular mechanical valve extraction (with transcatheter endovascular occlusion and cardioplegia) followed by direct ante-grade transcatheter heart valve implantation offers a potential solution to this conundrum. The procedure described is a novel technique that allows for the effective treatment of patients with failed mechanical surgical aortic valve prostheses in the setting of an inoperable porcelain aorta. In addition, a collaborative integrated multi-disciplinary heart team environment is required for the management of these complex patients.
Tricuspid valve vegetation debulking using the AngioVac system
Sripal Bangalore MD, MHA,Carlos L. Alviar MD,Susan Vlahakis CCP,Norma Keller MD,
doi : 10.1002/ccd.29519
Volume 98, Issue 3 p. E475-E477
Tricuspid valve endocarditis with recurrent septic pulmonary emboli is an indication for surgery. We present the case of a 36-year old man with tricuspid valve endocarditis and septic pulmonary emboli with percutaneous extraction of the vegetation. We discuss the nuances of such an approach and the need for more evidence in the management of these complex patients.
Aortic stenosis in the time of COVID-19: Development and outcomes of a rapid turnaround TAVI service
David Adlam DPhil FRCP,Nathan Chan MBBS,Julia Baron MD,Jan Kovac MD,
doi : 10.1002/ccd.29550
Volume 98, Issue 3 p. E478-E482
The COVID-19 pandemic has resulted in the cancellation of many elective surgical procedures. This has led to reports of an increase in mortality for patients with non-Covid health conditions due to delayed definitive management. Patients with severe aortic stenosis have a high annual mortality if left untreated. These patients are at risk due to the reduced number of surgical aortic valve replacements and competition for intensive care facilities during the COVID-19 pandemic. This case series suggests that the minimally invasive transcatheter aortic valve implantation is safe to continue during the COVID-19 pandemic with adjustments to the patient pathway to minimize hospital stay and to reduce patient and staff exposure. This helps to reduce the delay of definitive treatment for patients with severe aortic stenosis.
Interventional closure of aortomitral perforation after TAVR: A case report
Nils Petri MD,Bj?rn Lengenfelder MD,Wolfram Voelker MD,Peter Nordbeck MD,
doi : 10.1002/ccd.29561
Volume 98, Issue 3 p. E483-E485
Despite TAVR emerging as the gold standard for a broad spectrum of patients, it is associated with serious complications. In this report we present a case, where a TAVR procedure led to a perforation at the aortomitral continuity, discuss the risk factors for the occurrence of perforations and how we decided to treat the patient.
Recapture failure in transcatheter aortic valve replacement with CoreValve Evolut R
Nobuyasu Ito MD,Kan Zen MD, PhD,Kensuke Kuwabara MD,Satoaki Matoba MD, PhD,
doi : 10.1002/ccd.29580
Volume 98, Issue 3 p. E486-E489
Self-expanding prostheses for transcatheter aortic valve replacement (TAVR), which can be recaptured, provide us the option of repositioning for a more accurate placement. We report a very rare case in which the recapture of CoreValve Evolut R (Medtronic, Minneapolis, Minnesota) to correct the implantation depth during the deployment could not be achieved. We planned TAVR with a 23?mm Evolut R prosthesis for a 92-year-old female with severe aortic stenosis and tightly bent thoracic aorta. During the first deployment attempt, the implantation depth was greater than we expected at 2/3 deployment. They tried to recapture and reposition the prosthesis, but the prosthesis was not re-sheathed into the capsule of the delivery system. The prosthesis could not be recaptured despite a repeat attempt, and they were forced to deploy the device as it was. The prosthesis was deployed very carefully and implanted successfully without a pop-up into the ascending aorta. At a later date, this situation was replicated in vitro and was found that the distal segment of the capsule became deformed, increasing the resistance to rotating the grip handle.
Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after PCI: A meta-analysis
Rahman Shah MD,Ajay Labroo MD,Donnie A. Davis MD,Francis K. Le MD,
doi : 10.1002/ccd.29205
Volume 98, Issue 3 p. E490-E492
How to prevent thrombosis following transcatheter aortic valve replacement during durable left ventricular assist device supports
Teruhiko Imamura MD, PhD
doi : 10.1002/ccd.29268
Volume 98, Issue 3 p. E493-E493
